Provider review
Noom Med tirzepatide review
What Noom Med charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
We re-read Noom Med’s own pages on November 20, 2026. Its lowest all-in figure for compounded tirzepatide was $299 a month (ongoing monthly (billed quarterly)). Noom Med places =17 of 29 in our November 20, 2026 computed ranking, with 19 of the 40 points we measure for every program. Sections below that show July 2026 records are kept as dated history.
What is distinctive about this programme
A dose cap is not a discount
This is the clearest instance in our dataset of a pricing structure that requires explanation rather than comparison. Noom Med's $199 semaglutide programme is capped at a 0.6 mg maximum dose. The STEP trials that established semaglutide's weight-management efficacy used 2.4 mg.
A capped programme is not a cheaper version of the same treatment. It is a lower-dose treatment with a correspondingly smaller expected effect, and it should not appear in the same price ranking as full-titration programmes. Noom's own full-titration programme is $279, which is the figure that belongs in a like-for-like comparison.
We have kept the capped programme out of our cheapest-by-definition table for exactly this reason.
Introductory pricing and quarterly billing
The first month is $149 for tirzepatide against $299 ongoing. Introductory rates are excluded from every ranking on this site.
Quarterly billing sits between month-to-month and prepaid: less commitment than twelve months, less flexibility than monthly, and a three-month exposure if you stop.
Where the full programmes sit
At $279 semaglutide and $299 tirzepatide, Noom's full-titration programmes are in the upper band of the compounded market. Brand Zepbound is $299 direct from LillyDirect, and the approved oral orforglipron is $149 — both FDA-approved products at or below Noom's compounded tirzepatide price.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $199 | Reported |
| Tirzepatide injectable | $299 | Reported |
Where it holds up
- Publishes both a capped and a full-titration option rather than only the cheaper one
- Quarterly billing is a middle path between monthly and annual commitment
- Established consumer platform with an existing behavioural programme
Where it does not
- The $199 programme is capped at 0.6 mg, well below the trial dose
- Full-titration pricing is in the upper band of the compounded market
- Compounded tirzepatide at $299 matches brand Zepbound's manufacturer-direct starter price
- First-month rates are introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $199/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Category | Points |
|---|---|
| Pricing transparency | 20 pts |
| Total annual cost | 20 pts |
| Clinical oversight | 15 pts |
| Pharmacy transparency | 15 pts |
| Support | 10 pts |
| Regulatory disclosure | 10 pts |
| Accessibility | 10 pts |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Noom Med | prepaid | compounded injectable | — | $299 | — | $299 | Commitment tier | Reported | 2026-07-06 |
| Noom Med | prepaid | compounded injectable | — | $199 | — | $199 | Commitment tier | Reported | 2026-07-06 |
How this sits against the market
Show this figure as a table
| Program | All-in monthly | Read |
|---|---|---|
| Collective | $85.58 | Read 2026-10-15 |
| WellMedr | $89 | Read 2026-10-15 |
| Mondae | $114 | Read 2026-10-15 |
| NexLife | $115 | Read 2026-11-06 |
| Embody | $119 | Read 2026-10-15 |
| NextMeds | $119 | Read 2026-10-15 |
| SnagRx | $119 | Read 2026-10-15 |
| yourEra | $123 | Read 2026-10-15 |
| NewMeMeds | $125 | Older record, 2026-09-20 |
| CoreAge Rx | $129 | Read 2026-10-15 |
| Eden Health | $129 | Read 2026-10-15 |
| SkinnyRx | $129 | Older record, 2026-08-27 |
| GobyMeds | $133 | Read 2026-10-15 |
| Telos RX | $139 | Read 2026-10-15 |
| Sprout Health | $149 | Read 2026-10-15 |
| Strut Health | $149 | Read 2026-10-15 |
| He & She MD | $159 | Read 2026-10-15 |
| Bodybuilding Health+ | $174.67 | Read 2026-10-15 |
| bmiMD | $179 | Older record, 2026-09-17 |
| IVIM Health | $192 | Read 2026-10-15 |
| Alloy | $199 | Read 2026-10-15 |
| TelePep | $214 | Read 2026-10-15 |
| Yucca Health | $225 | Older record, 2026-09-12 |
| Found | $239 | Read 2026-10-15 |
| Pallas Health | $239 | Read 2026-10-15 |
| ShedRx | $239 | Read 2026-10-15 |
| MyDrHank | $240 | Older record, 2026-09-17 |
| Enhance.MD | $280 | Read 2026-10-15 |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
Pharmacy and fulfilment
Billing, cancellation and support
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Noom Med sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
Questions readers actually ask
Is Noom Med the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. Reviews here are not sponsored, and no provider can buy a score, a placement or a review. Tirzepatide Ranked is affiliate-supported; the disclosure page explains how.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Privacy PolicyCore & Trust
- Open GLP-1 Data and Evidence LibraryData
- Oak Longevity Tirzepatide ReviewProviders
Related coverage
Tirzepatide Ranked. “Noom Med Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/noom-med/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.